

Sun Pharmaceutical Industries Limited

SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



February 6, 2024

National Stock Exchange of India Limited
NSE Code: SUNPHARMA

BSE Limited
BSE Code: 524715

Subject - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Subsidiary Company

This is to inform that a subsidiary company with the name Sun Pharma Middle East FZ-LLC (UAE) is set up as a wholly-owned subsidiary of Sun Pharma (Netherlands) B.V., a subsidiary of the Company.

Particulars of the disclosure required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III are provided in the **Annexure A**.

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary & Compliance Officer
ICSI Membership No.: A23983

Annexure A

Disclosure under sub-para (1) i.e. Acquisition(s) (including agreement to acquire) of Para (A) of Part (A) of Schedule III to the Regulation 30 SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
1	Name of the target entity, details in brief such as size, turnover etc.;	Sun Pharma Middle East FZ-LLC (“SPME FZ-LLC”) is set up (has been issued a Commercial License) on 2 nd February 2024. SPME FZ-LLC is a wholly owned subsidiary of Sun Pharma (Netherlands) B.V., a subsidiary of the Company. The registered address of SPME FZ-LLC is at 907S, 9 th Floor, Dubai Science Park (DSP) Towers - South, Dubai, United Arab Emirates
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	SPME FZ-LLC is a newly set up company and therefore, it is not a related party transaction.
3	Industry to which the entity being acquired belongs;	Pharmaceutical
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	SPME FZ-LLC is set up as an entity to expand the business of the Company in UAE
5	Brief details of any governmental or regulatory approvals required for the acquisition;	Registration process would be completed upon approval by the relevant authority in UAE
6	Indicative time period for completion of the acquisition;	Not applicable as this intimation is about a newly set up subsidiary company
7	Nature of consideration - whether cash consideration or share swap and details of the same;	Initial capital consideration in cash
8	Cost of acquisition or the price at which the shares are acquired;	Not applicable as this intimation is about a newly set up subsidiary company
9	Percentage of shareholding/ control acquired and/ or number of shares acquired;	Sun Pharma (Netherlands) B.V. will own 100% equity in SPME FZ-LLC. The Company holds 100% in Sun Pharma (Netherlands) B.V.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	Not applicable as this intimation is about a newly set up subsidiary company